Interleukin-17 and innate immunity in infections and chronic inflammation

Research output: Contribution to journalArticle

Abstract

Interleukin 17 (IL-17) includes several cytokines among which IL-17A is considered as one of the major pro-inflammatory cytokine being central to the innate and adaptive immune responses. IL-17 is produced by unconventional T cells, members of innate lymphoid cells (ILCs), mast cells, as well as typical innate immune cells, such as neutrophils and macrophages located in the epithelial barriers and characterised by a rapid response to infectious agents by recruiting neutrophils as first line of defence and inducing the production of antimicrobial peptides. Th17 responses appear pivotal in chronic and acute infections by bacteria, parasites, and fungi, as well as in autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, and psoriatic arthritis. The data discussed in this review cumulatively indicate that innate-derived IL-17 constitutes a major element in the altered immune response against self antigens or the perpetuation of inflammation, particularly at mucosal sites. New drugs targeting the IL17 pathway include brodalumab, ixekizumab, and secukinumab and their use in psoriatic disease is expected to dramatically impact our approach to this systemic condition.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalJournal of Autoimmunity
Volume60
DOIs
Publication statusPublished - Jun 1 2015

Keywords

  • Brodalumab
  • Infection
  • Ixekizumab
  • Psoriasis
  • Psoriatic arthritis
  • Secukinumab

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Interleukin-17 and innate immunity in infections and chronic inflammation'. Together they form a unique fingerprint.

Cite this